LUND, SWEDEN--(Marketwire - Nov 9, 2012) -

· Laquinimod - Teva to initiate a new Phase III study in the US at year-end - milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe - Crohn's Phase II data presented at the UEGW conference

· TASQ - biomarker data presented at the ESMO conference - Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer

· ANYARA - Phase III study results to be presented Q1 2013

· 57-57 - clinical trial of systemic sclerosis/scleroderma is in progress

· ISI - project proceeding as planned

· Net sales: SEK 136.4 M (231.3)

· Operating loss: SEK 168.7 M (loss 6.2)

· Loss after tax: SEK 175.1 M (loss: 1.3)

· Loss per share for the period: SEK 2.54 (loss: 0.02)

This report is also available at www.activebiotech.com

Active Biotech AB Interim report January - September 2012: http://hugin.info/1002/R/1656396/535516.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1656396]